Evolution of insulin patents and market exclusivities in the USA

Lancet Diabetes Endocrinol. 2015 Nov;3(11):835-7. doi: 10.1016/S2213-8587(15)00364-2. Epub 2015 Oct 6.

Authors

Jing Luo¹, Aaron S Kesselheim²

Affiliations

¹ Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02120, USA. Electronic address: jluo1@partners.org.
² Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02120, USA.

PMID: 26453281
DOI: 10.1016/S2213-8587(15)00364-2

No abstract available

MeSH terms

Diabetes Mellitus / drug therapy
Drug Design
Drugs, Generic / economics*
Humans
Hypoglycemic Agents / economics*
Hypoglycemic Agents / therapeutic use
Insulin / economics*
Insulin / therapeutic use
Patents as Topic
United States

Substances

Drugs, Generic
Hypoglycemic Agents
Insulin